This article is more than 5 years old. Information may no longer be current.

MMC applied during glaucoma surgery may lower IOP

J Glaucoma. 2011;20(5):322-326.

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Intraoperative mitomycin C application may be a safe addition to nonpenetrating glaucoma surgery that aids in lowering IOP, a study found.

The meta-analysis reviewed eight clinical studies that compared surgery with and without MMC in patients with open-angle glaucoma. The weighted mean differences in IOP reduction rate between surgery with vs. without MMC were 5.24% at 6 months, 8.31% at 12 months, 9.56% at 24 months and 14.45% at 36 months. Surgery with MMC was associated with significantly greater success and no drug-induced complications.

The lack of observed complications may be linked to the fact that penetration into the anterior chamber is avoided with nonpenetrating surgery, possibly protecting against adverse events associated with MMC, the study authors said.

MMC dosing varied due to differing application times and concentrations. The study authors suggested that further research be conducted to determine optimal dosage.